249 related articles for article (PubMed ID: 24786774)
21. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
22. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
[TBL] [Abstract][Full Text] [Related]
23. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
24. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
25. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca
Jakubowska MA; Kerkhofs M; Martines C; Efremov DG; Gerasimenko JV; Gerasimenko OV; Petersen OH; Bultynck G; Vervliet T; Ferdek PE
Br J Pharmacol; 2019 Nov; 176(22):4402-4415. PubMed ID: 30266036
[TBL] [Abstract][Full Text] [Related]
26. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
27. Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis.
Adem J; Ropponen A; Eeva J; Eray M; Nuutinen U; Pelkonen J
J Immunother; 2016 Jan; 39(1):8-14. PubMed ID: 26641257
[TBL] [Abstract][Full Text] [Related]
28. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
29. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.
Pallis M; Burrows F; Ryan J; Grundy M; Seedhouse C; Abdul-Aziz A; Montero J; Letai A; Russell N
Oncotarget; 2017 Mar; 8(10):16220-16232. PubMed ID: 27092880
[TBL] [Abstract][Full Text] [Related]
30. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
31. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.
Soderquist RS; Danilov AV; Eastman A
J Biol Chem; 2014 Jun; 289(23):16190-9. PubMed ID: 24778183
[TBL] [Abstract][Full Text] [Related]
32. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
33. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).
Shajahan AN; Dobbin ZC; Hickman FE; Dakshanamurthy S; Clarke R
J Biol Chem; 2012 May; 287(21):17682-17692. PubMed ID: 22433870
[TBL] [Abstract][Full Text] [Related]
35. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.
Meynet O; Zunino B; Happo L; Pradelli LA; Chiche J; Jacquin MA; Mondragón L; Tanti JF; Taillan B; Garnier G; Reverso-Meinietti J; Mounier N; Michiels JF; Michalak EM; Carles M; Scott CL; Ricci JE
Blood; 2013 Oct; 122(14):2402-11. PubMed ID: 23966420
[TBL] [Abstract][Full Text] [Related]
36. Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
Lever JR; Fergason-Cantrell EA
Pharmacol Res; 2019 Apr; 142():87-100. PubMed ID: 30721730
[TBL] [Abstract][Full Text] [Related]
37. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1.
Guo Z; Song T; Xue Z; Liu P; Zhang M; Zhang X; Zhang Z
Eur J Pharm Sci; 2020 Jan; 142():105105. PubMed ID: 31669390
[TBL] [Abstract][Full Text] [Related]
38. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.
Johnson-Farley N; Veliz J; Bhagavathi S; Bertino JR
Leuk Lymphoma; 2015 Jul; 56(7):2146-52. PubMed ID: 25373508
[TBL] [Abstract][Full Text] [Related]
39. Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa.
Wang X; Gu Z; Li G; Zhang S; Cao Z; Yang Z; Liu G
Oncol Rep; 2014 Aug; 32(2):716-22. PubMed ID: 24891300
[TBL] [Abstract][Full Text] [Related]
40. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]